Eurofins Scientific (SWX:ESF) - Cotización, noticias y análisis

Resumen de acción ESF

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.

Acerca de la empresa

ESF fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	2/6
Financial Health	4/6
Dividends	4/6

Recompensas

Cotiza un 22.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 4.72%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Acciones altamente ilíquidas

Tiene un alto nivel de endeudamiento

Competidores de Eurofins Scientific SE

Bachem Holding

SWX:BANB

CHF6.0b

Tecan Group

SWX:TECN

CHF4.2b

Siegfried Holding

SWX:SFZN

CHF3.7b

Lonza Group

SWX:LONN

CHF37.5b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Eurofins Scientific
Historical stock prices
Current Share Price	€505.00
52 Week High	€0
52 Week Low	€0
Beta	0.58
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	900.79%
5 Year Change	851.04%
Change since IPO	2,177.85%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	ESF	CH Life Sciences	Mercado CH
7D	0%	-1.4%	-0.4%
1Y	0%	-10.5%	-4.5%

Rentabilidad vs. Industria: ESF superó al sector Swiss Life Sciences , que obtuvo un rendimiento del -11.4% el año pasado.

Rentabilidad vs. Mercado: ESF superó al mercado Swiss, que obtuvo un rendimiento del -4% el año pasado.

Volatilidad de los precios

Is ESF's price volatile compared to industry and market?
ESF volatility
ESF Average Weekly Movement	n/a
Life Sciences Industry Average Movement	3.9%
Market Average Movement	3.6%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	2.0%

Precio estable de las acciones: ESF no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de ESF en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1987	61,379	Gilles Martin	www.eurofins.com

Resumen de fundamentos de Eurofins Scientific SE

¿Cómo se comparan los beneficios e ingresos de Eurofins Scientific con su capitalización de mercado?
Estadísticas fundamentales de ESF
Capitalización bursátil	CHF11.34b
Beneficios(TTM)	CHF564.71m
Ingresos (TTM)	CHF6.53b

20.1x

Ratio precio-beneficio (PE)

1.7x

Ratio precio-ventas (PS)

¿Está ESF sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ESF
Ingresos	€6.71b
Coste de los ingresos	€5.19b
Beneficio bruto	€1.53b
Otros gastos	€945.40m
Beneficios	€580.90m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	3.01
Margen bruto	22.74%
Margen de beneficio neto	8.65%
Ratio deuda/patrimonio	57.7%

¿Cómo se ha desempeñado ESF a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.7%

Rentabilidad actual por dividendo

33%

Ratio de pagos

Resumen de acción ESF

Recompensas

Análisis de riesgos

Competidores de Eurofins Scientific SE

SWX:BANB

CHF6.0b

SWX:TECN

CHF4.2b

SWX:SFZN

CHF3.7b

SWX:LONN

CHF37.5b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023

Full year 2022 earnings released: EPS: €3.16 (vs €3.91 in FY 2021)

Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023

Recent updates

Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023

Full year 2022 earnings released: EPS: €3.16 (vs €3.91 in FY 2021)

Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023

Eurofins Scientific SE to Report Q3, 2022 Results on Oct 18, 2022

Eurofins Scientific SE (ENXTPA:ERF) signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Eurofins Scientific SE (ENXTPA:ERF) acquired Wessling Hungary Kornyezetvedelmi, Elelmiszerbiztonsagi, Egeszsegvedelmi Es Minosegugyi Sz.

First half 2022 earnings released: EPS: €1.62 (vs €2.09 in 1H 2021)

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Upcoming dividend of €1.00 per share

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire unknown majority stake in Ajal for Laboratories from Saudi Ajal Laboratories.

Eurofins Scientific SE (ENXTPA:ERF) acquires an unknown majority stake in Repertoire Genesis Inc.

Health Canada Approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Eurofins Scientific SE to Report Q1, 2022 Results on Apr 21, 2022

Eurofins’ empowerDX Launches PFAS Exposure™ in the U.S, the First at-Home Blood Test to Detect and Measure 40+ PFAS Compounds

Eurofins Technologies Launches New Lateral Flow Reader Rapidscan ST5-W as Single Platform Validated for Multiple Food and Environmental Rapid Tests

Eurofins Scientific SE (ENXTPA:ERF) entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342).

Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B

First half 2021 earnings released: EPS €2.17 (vs €0.43 in 1H 2020)

Eurofins Scientific SE (ENXTPA:ERF) acquired bioskin GmbH.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 India Sars-Cov-2 Variant

Eurofins Scientific Adds Virus Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

Eurofins Environment Testing America Expands Reporting to 75 Compounds

Full year 2020 earnings released: EPS €2.71 (vs €0.82 in FY 2019)

Revenue beats expectations

Eurofins Scientific SE to Report Fiscal Year 2020 Results on Mar 01, 2021

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire Beacon Discovery, Inc.

Eurofins Adds Virus Variant Distinction to its Sars-Cov-2 Monitoring Solution for Wastewater, Food and Environmental Surfaces

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices

Eurofins Genomics Launches Cost-Effective SARS-CoV-2 Full-Length Viral Genome Sequencing Services Essential in the Identification of Viral Mutations

Eurofins U.S. Clinical Diagnostic Laboratories At-Home COVID-19 Test Now Being Offered in All 50 States

Eurofins Technologies Launches New and Improved Lateral Flow Device Product Line for Allergen Detection in Foodstuffs and Environmental Samples

Eurofins Scientific SE (ENXTPA:ERF) acquired Taiyo Techno Research.

Market bids up stock over the past week

Eurofins Launches Sensitive, Fast and Cost-effective High Throughput SARS-CoV-2 Test Kits for Widely Available Sanger Sequencing Equipment

Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test

Eurofins Scientific Se Launches Europe’S First Validated Test Method to Evaluate Filtration Capacity of Masks for Sars-Cov-2

Eurofins Scientific SE (ENXTPA:ERF) acquired SunDream Environmental Technical Co. Ltd., Blue Formosa Environmental Technical Co. Ltd., and Universe Environmental Technology Co. Ltd.

First half earnings released

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Eurofins Scientific SE

20.1x

1.7x

Beneficios e Ingresos

Dividendos

1.7%

33%